Novaseek Research Launches Clinical Data Network for Research (CDNR) Platform

Boston, MA, October 1, 2015 – Novaseek Research today unveiled the Clinical Data Network for Research (CDNR) platform, the industry’s first comprehensive platform providing researchers in the life science industry and academia with access to real-world real-time clinical patient data and human biospecimens in compliance with HIPAA.

Access to data and biospecimens is essential to understanding diseases and developing novel therapies, especially in the era of precision medicine. Using Novaseek’s CDNR platform across all phases of discovery and development will help researchers to generate powerful new insights, increase R&D productivity and decrease project risk in the pursuit of new cures.

“Today, more than ever before, industry and academia need access to clinical data and biospecimens to accelerate discovery and translational studies. However, identifying the right patient at the right time and getting access to data and biospecimens is a chronic problem that continues to delay, or worse, derail vital research and development projects,” said Dr. Kate Torchilin, CEO, Novaseek Research. “Novaseek’s CDNR platform resolves these problems by enabling researchers to incorporate patient data and specimens into their discovery programs.”

The Novaseek CDNR platform enables researchers to access:

• Real world and real time clinical data made easy to use in R&D: Once implemented, the CDNR platform is updated daily with coded patient data extracted from electronic medical records from partner hospitals, including hard to reach community hospitals and physician groups. CDNR’s build-in data analytic tools allow researchers to navigate this complex information, assess project feasibility, improve patient identification and biospecimen sourcing criteria, and develop realistic project budgets and timelines.​
• Biospecimens richly annotated with clinical patient data: The CDNR platform gives researchers the ability to tap into a vast reservoir of remnant biospecimens in hospital central laboratories. All biospecimens are selected based upon specified patient and specimen criteria, including specimen type, patient demographics, lab test results, diagnoses, and medications.

Dr. Torchilin added, “The Novaseek CDNR makes it easy for hospitals and other healthcare provider organizations to support research in industry, academia, and government, without deviation from hospital workflows. The platform identifies consented cases that match complex clinical criteria, allowing laboratory staff to intercept samples and provide them for research. Importantly, all data and specimens are provided in compliance with HIPAA.”

The CDNR platform is currently available to early adopters in industry, academia and government. Preferential CDNR license terms are offered until the end of year 2015. Requests should be send to: info@novaseekresearch.com
​
About Novaseek
Novaseek is transforming how biomedical researchers access clinical data and human biospecimens to accelerate R&D. The Novaseek Clinical Data Network for Research (CDNR) is the industry’s first comprehensive platform enabling researchers to access real-world, real-time clinical data and large quantities of high quality biospecimens – that is essential for understanding disease and developing medical advances – all in compliance with HIPAA. Incorporating Novaseek’s CDNR platform across all phases of research and development helps industry and academia generate powerful new insights, increases R&D productivity and decreases risk in the pursuit of new cures. The CDNR platform was developed by experts in drug development, hospital operations and health IT to create a win-win for industry, academia, healthcare providers and patients.